Wedbush Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
Wedbush analyst Yun Zhong maintained a Buy rating on Sarepta Therapeutics today and set a price target of $29.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Zhong is an analyst with an average return of -6.2% and a 42.55% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Ascendis Pharma, and BioMarin Pharmaceutical.
In addition to Wedbush, Sarepta Therapeutics also received a Buy from Wells Fargo’s Yanan Zhu in a report issued on February 27. However, today, H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (NASDAQ: SRPT).
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $399.36 million and a GAAP net loss of $179.95 million. In comparison, last year the company earned a revenue of $467.17 million and had a net profit of $33.61 million
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in December 2025, Ian Michael Estepan, the COO of SRPT sold 13,187.00 shares for a total of $294,201.97.
Read More on SRPT:
Disclaimer & DisclosureReport an Issue
- Sarepta price target lowered to $38 from $45 at Wells Fargo
- Sarepta price target lowered to $20 from $22 at Baird
- Sarepta downside risks outweigh upside potential, says Citi
- Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
- Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside
